Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leqvio under the microscope: real-world safety study launched for cholesterol drug

NCT ID NCT06770543

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 1,500 adults with high cholesterol who are prescribed Leqvio (inclisiran) in routine care. The goal is to monitor side effects and measure how well the drug lowers LDL cholesterol. It is a mandatory safety review required by Korean health authorities, not a test of a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Yangsan, Gyeongsangnam-do, 50612, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 49241, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Taegu, 41944, South Korea